

**Fortis Healthcare Limited**

Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

Emergency : 105010

Email : secretarial@fortishealthcare.com

Website : www.fortishealthcare.com

FHL/SEC/2024-25

October 29, 2024

The National Stock Exchange of India Ltd.
Scrip Symbol: FORTIS

BSE Limited
Scrip Code:532843

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations,2015

Dear Madam/Sir,

In furtherance to our earlier announcement dated August 30, 2024 and pursuant to the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015 (“**SEBI Listing Regulations**”), this is to inform you that the Company has today received approval of the Competition Commission of India (“**CCI**”) for acquisition of the entire stake held by International Finance Corporation, NYLIM Jacob Ballas India Fund III LLC and Resurgence PE Investments Limited (**collectively referred to as “PE Investors**”) in Agilus Diagnostics Limited (“**Agilus**”), a material subsidiary of the Company. The detailed order issued by the CCI in this respect shall follow.

The time of occurrence of event is 17:46 Hours (IST).

This is for your information and record.

Thanking You,

Yours Sincerely,
For **Fortis Healthcare Limited**

Satyendra Chauhan
Company Secretary & Compliance Officer
M. No. A14783